Fact-check: Mayo Clinic Minute on weaning off weight-loss medications

What the video covers

A Mayo Clinic News Network minute: the scale is moving, you want to stop; how long can you stay on these drugs; a clinician says the class has not been used long enough to know what happens at three or five years; some studies show regain after stopping; stopping within about six months carries a very high chance of regain; the drug changes appetite signals and the body returns to its default without it; talk to a health professional before stopping, eat a balanced diet and stay active.

What it gets right

The core message is what the randomised withdrawal trials found. In STEP 4, after 20 weeks on semaglutide 2.4 mg, people switched to placebo regained 6.9 percent of body weight over the next 48 weeks while those who continued lost a further 7.9 percent (PubMed 33755728). In SURMOUNT-4, after 36 weeks on tirzepatide during which participants lost 20.9 percent, those switched to placebo regained 14.0 percent over the following 52 weeks while those who continued lost a further 5.5 percent (PubMed 38078870). "Appetite signals go back to default" is a fair lay description of why.

The advice to involve a clinician before stopping is correct for a further reason the video does not have time for: people with type 2 diabetes will see glucose rise, and anyone whose blood-pressure or other medications were reduced during weight loss may need them adjusted again.

What it leaves out or overstates

The "six months" threshold is not from a trial; both withdrawal trials stopped the drug at a fixed point and regain followed regardless. There is no evidence that staying on longer protects against regain after stopping, and the video's phrasing could be read that way.

The line that the class has not been used long enough to know what happens in three to five years was already conservative when recorded in 2024 and is now out of date for semaglutide: SELECT followed 17,604 people for a mean of 3.3 years with a maximum beyond four (PubMed 37952131), and the class has been prescribed for type 2 diabetes since 2005. Long-term data on weight maintenance specifically remain shorter than for glycaemic use, which is a fair point the video compresses.

No mention of tapering, which some clinicians use and which has not been tested in a randomised trial, nor of the option of a lower maintenance dose, which SURMOUNT-4 did not test either.

Where to go next

The maintenance planner on Weight Loss on GLP-1s applies the STEP 4 and SURMOUNT-4 arithmetic to your own weight and builds a question list for your prescriber. Stopping and maintenance has a full guide on FormBlends Guides. The Yale videos in the obesity science playlist explain the set-point biology behind regain. FormBlends' products are at formblends.com; compounded GLP-1s are not FDA approved and were not studied in either withdrawal trial.